Health Economics›Non-small cell lung cancer›Advanced or metastatic disease first-line elderly or poor performance status

Advanced or metastatic disease first-line elderly or poor performance status

Non-small cell lung cancer · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 44 549	21d	~6.8 mo	~12.6 mo	~5	~R 221 407 PFS proxy · indirect	2
Pemetrexed and Bevacizumab Variant #01	—	R 43 211	21d	—	~23.3 mo	~2	~R 86 422 PFS proxy · indirect	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	20.2 mo	2	R 62 509 PFS proxy	2
Carboplatin and Pemetrexed Variant #01	—	R 14 563	21d	8.6 mo	13.3 mo	4	R 58 251 PFS proxy	6
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	—	5.3 mo	4	R 52 900 PFS proxy	1
Gemcitabine and Paclitaxel Variant #01	—	R 5 224	21d	—	9.8 mo	6	R 31 344 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	6.0 mo	10.0 mo	2	R 8 829 PFS proxy	7
Gemcitabine and Vinorelbine Variant #01	—	R 4 259	21d	—	6.7 mo	2	R 8 518 PFS proxy	2
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	6.0 mo	10.4 mo	6	R 23 595 PFS proxy	14
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	8.4 mo	8	R 23 372 PFS proxy	2
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	6.2 mo	7	R 11 705 PFS proxy	4
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	5.3 mo	10.3 mo	9	R 9 222 PFS proxy	32
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	6.2 mo	7	R 3 203 PFS proxy	3

13 of 13 regimens shown